After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
We are very excited to launch our new website! Please take a few moments to click around and explore...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...